IllnessProstate cancer, hereditary; Olaparib therapy

NGS +

Sanger

20-30% of men with metastatic, castration-resistant prostate cancer have inherited and/or somatic mutations in the BRCA genes, with only about 52 and 34% of those affected carrying a BRCA2 or BRCA1 mutation in the germ line (1, 2). Following breast, ovarian, peritoneal and pancreatic cancer, the PARP inhibitor olaparib has also been approved by the European Medicines Agency (EMA) for the treatment of patients with metastatic, castration-resistant prostate cancer who had previously received antihormone therapy or chemotherapy (3). The approval is based on the Phase III clinical trial PROfound, which demonstrated that patients with somatic BRCA1/2 mutations benefit from olaparib therapy. Progression-free survival of patients with BRCA-mutated tumors increased from 14.7 months (placebo) to 19.1 months on olaparib (2).

References:

(1) https://www.nejm.org/doi/10.1056/NEJMoa1911440

(2) https://ascopubs.org/doi/full/10.1200/PO.19.00345

(3) https://www.krebsinformationsdienst.de/fachkreise/nachrichten/2020/fk22-prostatakrebs-olaparib-lynparza-zulassung.php

• Alias: Olaparib-Therapie
• Prostata-Karzinom, hereditär